Yokukansan, a traditional Japanese medicine, decreases head-twitch behaviors and serotonin 2A receptors in the prefrontal cortex of isolation-stressed mice

Journal of Ethnopharmacology

Volumn 166, Issue , 2015, Pages 23-30

  Ueki, Toshiyuki ^a   Mizoguchi, Kazushige ^a   Yamaguchi, Takuji ^a   Nishi, Akinori ^a   Sekiguchi, Kyoji ^a   Ikarashi, Yasushi ^a   Kase, Yoshio ^a  

^a TSUMURA AND CO   (Japan)

Author keywords

Head twitch behavior; Mouse; Prefrontal cortex; Serotonin 2A receptor; Traditional Japanese medicine; Yokukansan

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; KETANSERIN; PLANT EXTRACT; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; TRITIUM; UNCLASSIFIED DRUG; YOKUKANSAN; 4-IODO-2,5-DIMETHOXYPHENYLISOPROPYLAMINE; AMPHETAMINE DERIVATIVE; BUPLEURUM ROOT EXTRACT; HERBACEOUS AGENT; SEROTONIN 2 AGONIST; YI-GAN SAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BUPLEURUM; CELL MEMBRANE; CNIDIUM; CONTROLLED STUDY; GLYCYRRHIZA; HALLUCINATION; HEAD TWITCH; JAPANESE ANGELICA ROOT; MALE; MEDICINAL PLANT; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PSYCHOPHARMACOTHERAPY; RECEPTOR BINDING ASSAY; RECEPTOR DOWN REGULATION; SCATCHARD PLOT; SOCIAL ISOLATION; UNCARIA HOOK; ANGELICA; ANIMAL; ANIMAL BEHAVIOR; CHEMISTRY; CHINESE MEDICINE; DOWN REGULATION; DRUG EFFECTS; ETHNOPHARMACOLOGY; HALLUCINATIONS; METABOLISM; PROCEDURES; TRADITIONAL MEDICINE; UNCARIA;

ANIMALIA; BUPLEURUM; GLYCYRRHIZA; MUS; UNCARIA;

AMPHETAMINES; ANGELICA; ANIMALS; BEHAVIOR, ANIMAL; BUPLEURUM; DOWN-REGULATION; DRUGS, CHINESE HERBAL; ETHNOPHARMACOLOGY; GLYCYRRHIZA; HALLUCINATIONS; MALE; MEDICINE, KAMPO; MEDICINE, TRADITIONAL; MICE; PLANT EXTRACTS; PREFRONTAL CORTEX; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN 5-HT2 RECEPTOR AGONISTS; UNCARIA;

EID: 84925428061     PISSN: 03788741     EISSN: 18727573     Source Type: Journal    
DOI: 10.1016/j.jep.2015.02.046     Document Type: Article

References (60)

1. S. Ali, M. Patel, S. Jabeen, R.K. Bailey, T. Patel, M. Shahid, W.J. Riley, and A. Arain Insight into delirium Innovat. Clin. Neurosci. 8 2011 25 34
2. A.F. Arnsten Prefrontal cortical network connections: key site of vulnerability in stress and schizophrenia Int. J. Dev. Neurosci. 29 2011 215 223
3. N.M. Barnes, and T. Sharp A review of central 5-HT receptors and their function Neuropharmacology 38 1999 1083 1152
4. G.D. Bartoszyk, C. van Amsterdam, H. B n Amst, and C.A. Seyfried EMD 281014, a new selective serotonin 5-HT2A receptor antagonist Eur. J. Pharmacol. 473 2003 229 230
5. G. Beaubrun, and G.E. Gray A Review of Herbal Medicines for Psychiatric Disorders 51 2000 Psychiatric Services Washington, DC 1130 1134
6. P. Bedard, and C.J. Pycock "Wet-dog" shake behaviour in the rat: a possible quantitative model of central 5-hydroxytryptamine activity Neuropharmacology 16 1977 663 670
7. E.A. Carlini Plants and the central nervous system Pharmacol., Biochem. Behav. 75 2003 501 512
8. J. Cerejeira, P. Batista, V. Nogueira, A. Vaz-Serra, and E.B. Mukaetova-Ladinska The stress response to surgery and postoperative delirium: evidence of hypothalamic-pituitary-adrenal axis hyperresponsiveness and decreased suppression of the GH/IGF-1 axis J. Geriatr. Psychiatry Neurol. 26 2013 185 194
9. J.J. Cerqueira, F. Mailliet, O.F. Almeida, T.M. Jay, and N. Sousa The prefrontal cortex as a key target of the maladaptive response to stress J. Neurosci. 27 2007 2781 2787
10. C.I. Cohen, I. Izediuno, A.M. Yadack, B. Ghosh, and M. Garrett Characteristics of auditory hallucinations and associated factors in older adults with schizophrenia Am. J. Geriatr. Psychiatry pii: S1064-7481 13 2013 00289-3
11. S.J. Corne, and R.W. Pickering A possible correlation between drug-induced hallucinations in man and a behavioral response in mice Psychopharmacologia 11 1967 65 78
12. S.J. Corne, R.W. Pickering, and B.T. Warner A method for assessing the effects of drugs on the central actions of 5-hydroxytryptamine Br. J. Pharmacol. Chemother. 20 1963 106 120
13. N.A. Darmani, B.R. Martin, U. Pandey, and R.A. Glennon Do functional relationships exist between 5-HT1A and 5-HT2 receptors? Pharmacol., Biochem. Behav. 36 1990 901 906
14. M.E. Dawson, A.M. Schell, A. Rissling, J. Ventura, K.L. Subotnik, and K.H. Nuechterlein Psychophysiological prodromal signs of schizophrenic relapse: a pilot study Schizophr. Res. 123 2010 64 67
15. Y. Dwivedi, A.C. Mondal, G.V. Payappagoudar, and H.S. Rizavi Differential regulation of serotonin (5HT)2A receptor mRNA and protein levels after single and repeated stress in rat brain: role in learned helplessness behavior Neuropharmacology 48 2005 204 214
16. N. Egashira, K. Mishima, T. Uchida, N. Hasebe, H. Nagai, A. Mizuki, K. Iwasaki, H. Ishii, R. Nishimura, Y. Shoyama, and M. Fujiwara Anandamide inhibits the DOI-induced head-twitch response in mice Psychopharmacology 171 2004 382 389
17. N. Egashira, K. Iwasaki, A. Ishibashi, K. Hayakawa, R. Okuno, M. Abe, N. Uchida, K. Mishima, K. Takasaki, R. Nishimura, R. Oishi, and M. Fujiwara Repeated administration of yokukansan inhibits DOI-induced head-twitch response and decreases expression of 5-hydroxytryptamine (5-HT) 2A receptors in the prefrontal cortex Prog. Neuro-Psychopharmacol. Biol. Psychiatry 32 2008 1516 1520
18. A.S. Eison, and U.L. Mullins Regulation of central 5-HT2A receptors: a review of in vivo studies Behav. Brain Res. 73 1996 177 181
19. C. Fernandes, C.R. McKittrick, S.E. File, and B.S. McEwen Decreased 5-HT1A and increased 5-HT2A receptor binding after chronic corticosterone associated with a behavioural indication of depression but not anxiety Psychoneuroendocrinology 22 1997 477 491
20. R.A. Glennon Do classical hallucinogens act as 5-HT2 agonists or antagonists? Neuropsychopharmacology 3 1990 509 517
21. V.E. Golimbet, O.M. Lavrushina, V.G. Kaleda, L.I. Abramova, and T.V. Lezheiko Supportive evidence for the association between the T102C 5-HTR2A gene polymorphism and schizophrenia: a large-scale case-control and family-based study Eur. Psychiatry 22 2007 167 170
22. J. González - Maeso, N.V. Weisstaub, M. Zhou, P. Chan, L. Ivic, R. Ang, A. Lira, M. Bradley-Moore, Y. Ge, Q. Zhou, S.C. Sealfon, and J.A. Gingrich Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior Neuron 53 2007 439 452
23. S. Grover, S. Chakrabarti, R. Shah, and V. Kumar A factor analytic study of the Delirium Rating Scale-Revised-98 in untreated patients with delirium J. Psychosom. Res. 70 2011 473 478
24. Y. Hayashi, Y. Ishida, T. Inoue, M. Udagawa, K. Takeuchi, H. Yoshimuta, K. Kiue, Y. Ninomiya, J. Kawano, T. Sameshima, T. Kawahara, I. Goto, K. Shudo, S. Kurayama, J. Nakamura, K. Okahara, and Y. Mitsuyama Treatment of behavioral and psychological symptoms of Alzheimer-type dementia with yokukansan in clinical practice Prog. Neuro-Psychopharmacol. Biol. Psychiatry 34 2010 541 545
25. Y. Ikarashi, S. Iizuka, S. Imamura, T. Yamaguchi, K. Sekiguchi, H. Kanno, Z. Kawakami, M. Yuzurihara, Y. Kase, and S. Takeda Effects of Yokukansan, a traditional Japanese medicine, on memory disturbance and behavioral and psychological symptoms of dementia in thiamine-deficient rats Biol. Pharm. Bull. 32 2009 1701 1709
26. K. Iwasaki, T. Satoh-Nakagawa, M. Maruyama, Y. Monma, M. Nemoto, N. Tomita, H. Tanji, H. Fujiwara, T. Seki, M. Fujii, H. Arai, and H. Sasaki A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients J. Clin. Psychiatry 66 2005 248 252
27. J. Kazmierski, A. Banys, J. Latek, J. Bourke, and R. Jaszewski Cortisol levels and neuropsychiatric diagnosis as markers of postoperative delirium: a prospective cohort study Crit. Care 17 2013 R38
28. S. Kienzle-Horn Herbal medicines for neurological diseases Curr. Opin. Investig. Drugs 3 2002 763 767
29. N. Kurauchi The 19th Conference on Surgery and Kampo Medicine, Workshop 1-4 Prog. Med. 30 2010 102 103 in Japanese
30. F. Lafaille, S.A. Welner, and B.E. Suranyi-Cadotte Regulation of serotonin type 2 (5-HT2) and beta-adrenergic receptors in rat cerebral cortex following novel and classical antidepressant treatment J. Psychiatry Neurosci. 16 1991 209 214
31. I. Lucki, M.S. Nobler, and A. Frazer Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat J. Pharmacol. Exp. Ther. 228 1984 133 139
32. J.B. Malick, E. Doren, and A. Barnett Quipazine-induced head-twitch in mice Pharmacol., Biochem. Behav. 6 1977 325 329
33. B. Maneeton, N. Maneeton, M. Srisurapanont, and K. Chittawatanarat Quetiapine versus haloperidol in the treatment of delirium: a double-blind, randomized, controlled trial Drug Des., Dev. Ther. 7 2013 657 667
34. J.R. Martin, M. B Ru, F. Jenck, J. Moreau, V. Mutel, A.J. Sleight, J. Wichmann, J.S. Andrews, H.H. Berendsen, C.L. Broekkamp, G.S. Ruigt, Ku S.T.C., and A.M. Delft 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential J. Pharmacol. Exp. Ther. 286 1998 913 924
35. Y. Matsuda, T. Kishi, H. Shibayama, and N. Iwata Yokukansan in the treatment of behavioral and psychological symptoms of dementia: a systematic review and meta-analysis of randomized controlled trials Human Psychopharmacol. 28 2013 80 86
36. P.L. Miller, S.M. Lawrie, A. Hodges, R. Clafferty, R. Cosway, and E.C. Johnstone Genetic liability, illicit drug use, life stress and psychotic symptoms: preliminary findings from the Edinburgh study of people at high risk for schizophrenia Soc. Psychiatry Psychiatr. Epidemiol. 36 2001 338 342
37. T. Miyaoka, M. Furuya, H. Yasuda, M. Hayashida, A. Nishida, T. Inagaki, and J. Horiguchi Yi-gan san as adjunctive therapy for treatment-resistant schizophrenia: an open-label study Clin. Neuropharmacol. 32 2009 6 9
38. K. Mizoguchi, Y. Tanaka, and T. Tabira Anxiolytic effect of a herbal medicine, yokukansan, in aged rats: involvement of serotonergic and dopaminergic transmissions in the prefrontal cortex J. Ethnopharmacol. 127 2010 70 76
39. K. Mizoguchi, M. Yuzurihara, A. Ishige, H. Sasaki, D.H. Chui, and T. Tabira Chronic stress induces impairment of spatial working memory because of prefrontal dopaminergic dysfunction J. Neurosci. 20 2000 1568 1574
40. A. Monji, M. Takita, T. Samejima, T. Takaishi, K. Hashimoto, H. Matsunaga, M. Oda, Y. Sumida, Y. Mizoguchi, T. Kato, H. Horikawa, and S. Kanba Effect of yokukansan on the behavioral and psychological symptoms of dementia in elderly patients with Alzheimerls disease Prog. Neuro-Psychopharmacol. Biol. Psychiatry 33 2009 308 311
41. P.S. Murray, S. Kumar, M.A. Demichele-Sweet, and R.A. Sweet Psychosis in Alzheimerls disease Biol. Psychiatry pii: S0006-3223 13 2013 00773-7
42. A. Nishi, T. Yamaguchi, K. Sekiguchi, S. Imamura, M. Tabuchi, H. Kanno, Y. Nakai, K. Hashimoto, Y. Ikarashi, and Y. Kase Geissoschizine methyl ether, an alkaloid in Uncaria hook, is a potent serotonin1A receptor agonist and candidate for amelioration of aggressiveness and sociality by Yokukansan Neuroscience 207 2012 124 136
43. K.H. Nuechterlein, M.E. Dawson, M. Gitlin, J. Ventura, M.J. Goldstein, K.S. Snyder, C.M. Yee, and J. Mintz Developmental processes in schizophrenic disorders: longitudinal studies of vulnerability and stress Schizophr. Bull. 18 1992 387 425
44. G. Ossowska, G. Nowak, B. Klenk-Majewska, Z. Danilczuk, and I. Zebrowska-Lupina Effect of imipramine on brain D-1 and 5-HT-2A receptors in a chronic unpredictable stress model in rats Pol. J. Pharmacol. 54 2002 89 93
45. A. Pazos, A. Probst, and J.M. Palacios Serotonin receptors in the human brain - IV. Autoradiographic mapping of serotonin-2 receptors Neuroscience 21 1987 123 139
46. A.L. Pritchard, J. Harris, C.W. Pritchard, J. Coates, S. Haque, and R. Holder Role of 5-HT2A and 5-HT2C polymorphisms in behavioural and psychological symptoms of Alzheimerls disease Neurobiol. Ageing 29 2008 341 347
47. M.V. Puig, P. Celada, L. Díaz-Mataix, and F. Artigas In vivo modulation of the activity of pyramidal neurons in the rat medial prefrontal cortex by 5-HT2A receptors: relationship to thalamocortical afferents Cereb. Cortex 13 2003 870 882
48. B.B. Quednow, K.U. K dn, R. M dnoww, S.G. Schwab, A. Schuhmacher, W. Maier, and M. Wagner Sensorimotor gating of schizophrenia patients is influenced by 5-HT2A receptor polymorphisms Biol. Psychiatry 64 2008 434 437
49. K. Sekiguchi, T. Yamaguchi, M. Tabuchi, Y. Ikarashi, and Y. Kase Effects of yokukansan, a traditional Japanese medicine, on aggressiveness induced by intracerebroventricular injection of amyloid beta protein into mice Phytother. Res. 23 2009 1175 1181
50. H. Shoji, and K. Mizoguchi Brain region-specific reduction in c-Fos expression associated with an anxiolytic effect of yokukansan in rats J. Ethnopharmacol. 149 2013 93 102
51. E. Syvälahti, J. Penttilä, H. Majasuo, E.P. Pälvimäki, A. Laakso, and J. Hietala Combined treatment with citalopram and buspirone: effects on serotonin 5-HT2A and 5-HT2C receptors in the rat brain Pharmacopsychiatry 39 2006 1 8
52. A. Takeda, H. Itoh, H. Tamano, M. Yuzurihara, and N. Oku Suppressive effect of yokukansan on excessive release of glutamate and aspartate in the hippocampus of zinc-deficient rats Nutr. Neurosci. 11 2008 41 46
53. K. Terawaki, Y. Ikarashi, K. Sekiguchi, Y. Nakai, and Y. Kase Partial agonistic effect of yokukansan on human recombinant serotonin 1A receptors expressed in the membranes of Chinese hamster ovary cells J. Ethnopharmacol. 127 2010 306 312
54. T. Ueda, S. Ugawa, Y. Ishida, and S. Shimada Geissoschizine methyl ether has third-generation antipsychotic-like actions at the dopamine and serotonin receptors Eur. J. Pharmacol. 671 2011 79 86
55. H.R. Wang, Y.S. Woo, and W.M. Bahk Atypical antipsychotics in the treatment of delirium Psychiatry Clin. Neurosci. 67 2013 323 331
56. J. Williams, G. Spurlock, P. McGuffin, J. Mallet, M.M. N llet, M. Gill, H. Aschauer, P.O. Nylander, F. Macciardi, and M.J. Owen Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group Lancet 347 1996 1294 1296
57. D.L. Willins, and H.Y. Meltzer Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats J. Pharmacol. Exp. Ther. 282 1997 699 706
58. T. Yamaguchi, A. Tsujimatsu, H. Kumamoto, T. Izumi, Y. Ohmura, T. Yoshida, and M. Yoshioka Anxiolytic effects of Yokukansan, a traditional Japanese medicine, via serotonin 5-HT1A receptors on anxiety-related behaviors in rats experienced aversive stress J. Ethnopharmacol. 143 2012 533 539
59. F.D. Yocca, A.S. Eison, D.K. Hyslop, E. Ryan, D.P. Taylor, and G. Gianutsos Unique modulation of central 5-HT2 receptor binding sites and 5-HT2 receptor-mediated behavior by continuous gepirone treatment Life Sci. 49 1991 1777 1785
60. H.J. Yoon, K.M. Park, W.J. Choi, S.H. Choi, J.Y. Park, J.J. Kim, and J.H. Seok Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium BMC Psychiatry 13 2013 240